IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July ...

In Trodelvy’s FDA-approved indication of metastatic triple-negative breast cancer (TNBC), the anti-TROP-2 drug cut the risk of disease progression by 59% over chemotherapy in patients who had ...

Trodelvy is a prescription drug used to treat certain types of breast cancer. Learn about the drug’s dosage, form, strength, and more.

Withhold Trodelvy for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Consider G-CSF for secondary prophylaxis.

Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated ...

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer.

Trodelvy has accelerated U.S. approval for treating advanced urothelial cancer, but Gilead on Thursday said a large trial failed to confirm that the drug improved survival.

Is Trodelvy's benefit clinically meaningful? When Gilead said in March that the study had hit its primary endpoint of improving progression-free survival (PFS), the company itself gave investors ...

Gilead Sciences, Inc. today announced new data from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy ® versus comparator chemotherapy in patients with HR+/ HER2 ...

At the American Society of Clinical Oncology (ASCO) Annual Meeting, held 30 May-3 June 2025, primary results were presented from the ASCENT-04/KEYNOTE-D19 study investigating Gilead’s Trodelvy ...

FOSTER CITY, Calif., September 05, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) will present new data from the company’s broad lung cancer clinical development program during the IASLC 2024 World ...

Trodelvy ® Plus Keytruda ® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer – First Pivotal ...